Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 1.00 |
| ▸ | FAAH | O00519 | 4/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.71 |
| ▸ | PRKCA | P17252 | 1/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.70 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.70 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.70 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.70 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.70 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.70 |
| ▸ | CES2 | O00748 | 1/20 | 0.70 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.70 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glyceryl Monooleate SCHEMBL1237693 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL16083709 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL4398941 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL15604 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL20719833 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL18970879 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL5158478 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL20719803 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL20719744 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL4065294 | 1.00 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | MELBOURNE INST TECH (AU) | 2025-11-06 | — | — | US | claimed |
| US-20250325256-A1 | LIPID PATCH | SENSACH AB (SE) | 2025-10-23 | — | — | US | claimed |
| EP-4531812-A1 | LIPID NANOCARRIER VACCINE | Royal Melbourne Institute of Technology (AU) | 2025-04-09 | — | — | EP | claimed |
| CN-119546282-A | Lipid nanocarrier vaccine | 皇家墨尔本理工大学 | 2025-02-28 | — | — | CN | claimed |
| EP-4419884-A2 | LIPID PATCH | Sensach AB (SE) | 2024-08-28 | — | — | EP | claimed |
| US-20230404921-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-12-21 | — | — | US | claimed |
| WO-2023225722-A1 | LIPID NANOCARRIER VACCINE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-11-30 | — | — | WO | claimed |
| CN-116804677-A | Biomarker for early detection of aspiration pneumonia and application thereof | 福建医科大学附属第二医院 | 2023-09-26 | — | — | CN | claimed |
| EP-4236916-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | Royal Melbourne Institute of Technology (AU) | 2023-09-06 | — | — | EP | claimed |
| WO-2023121603-A1 | PRODUCT ENABLING DISINFECTION AND PROTECTION OF THE SKIN | ECZACIBASI TUKETIM URUNLERI SANAYI VE TICARET ANONIM SIRKETI (TR) | 2023-06-29 | — | — | WO | claimed |
| WO-2023066990-A2 | LIPID PATCH | ENGBLOM JOHAN (SE) | 2023-04-27 | — | — | WO | claimed |
| WO-2022087686-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2022-05-05 | — | — | WO | claimed |
| CN-109549927-B | Solid solution compositions and their use in cardiovascular disease | 因佛斯特医疗有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-100586488-C | Dyed polymethyl methacrylate bone cement and process for its production | HERAEUS KULZER GMBH | 2010-02-03 | — | — | CN | claimed |
| CN-1891306-A | Dyed polymethyl methacrylate bone cement and process for its production | HERAEUS KULZER GMBH (DE) | 2007-01-10 | — | — | CN | claimed |
| CN-1189215-C | Formulation solubilizing water-insoluble agents and preparation method thereof | KOREA INST SCI & TECH (KR) | 2005-02-16 | — | — | CN | claimed |
| CN-1422163-A | Formulation for solubilizing water-insoluble agents and process for preparing same | KOREA INST SCI & TECH (KR) | 2003-06-04 | — | — | CN | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| CN-1422163-A | Formulation for solubilizing water-insoluble agents and process for preparing same | KOREA INST SCI & TECH (KR) | 2003-06-04 | — | — | CN | disclosed |
| WO-1991007168-A1 | RIBOFLAVIN AS A TANNING ENHANCER | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | DGKA 1543/4885FAAH 252/4885KDM4E 3287/4885 |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | CD47, LY96, TSG101 | DGKA 826/4885FAAH 1756/4885KDM4E 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.